| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 99.31M | — |
| Operating expense | — | — |
| Net income | -47.31M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, 2LB.F returned +206.1% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +188.8% |
| 1 year | +206.1% |
| 5 years | -66.0% |
| 10 years | -4.6% |
| All-time high | €39.03 (Dec 2020) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in 2LB.F would be worth today ›No. Iovance Biotherapeutics, Inc. has not paid a dividend in the past 12 months.
Iovance Biotherapeutics, Inc. is part of the Healthcare sector.
Iovance Biotherapeutics, Inc. has a market cap of 3.06B EUR, based on the latest quote.
Iovance Biotherapeutics, Inc. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
